Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.55
Percentage change 3.34	%

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI VB IWM VXF VBK IWO CGGR AVUV IBB VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.51	Insider Own	11.19%	Shs Outstand	111.48M	Perf Week	-11.04%
Market Cap	1.90B	Forward P/E	-	EPS next Y	-1.75	Insider Trans	-0.67%	Shs Float	99.01M	Perf Month	2.10%
Income	-164.19M	PEG	-	EPS next Q	-0.38	Inst Own	85.15%	Short Float	5.45%	Perf Quarter	-15.76%
Sales	621.71M	P/S	3.05	EPS this Y	-4.67%	Inst Trans	4.06%	Short Ratio	5.54	Perf Half Y	-44.28%
Book/sh	3.25	P/B	5.24	EPS next Y	-6.91%	ROA	-13.85%	Short Interest	5.40M	Perf Year	-25.50%
Cash/sh	8.35	P/C	2.04	EPS next 5Y	8.60%	ROE	-45.52%	52W Range	14.17 - 34.13	Perf YTD	-42.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-83.87%	ROI	-32.86%	52W High	-50.19%	Beta	0.75
Dividend TTM	-	Quick Ratio	1.41	Sales past 5Y	11.49%	Gross Margin	77.31%	52W Low	19.97%	ATR (14)	0.97
Dividend Ex-Date	-	Current Ratio	1.47	EPS Y/Y TTM	16.28%	Oper. Margin	-26.69%	RSI (14)	43.78	Volatility	2.38% 3.81%
Employees	1488	Debt/Eq	1.92	Sales Y/Y TTM	18.27%	Profit Margin	-26.41%	Recom	1.57	Target Price	32.57
Option/Short	Yes / Yes	LT Debt/Eq	0.38	EPS Q/Q	13.87%	Payout	-	Rel Volume	2.92	Prev Close	16.45
Sales Surprise	5.48%	EPS Surprise	33.20%	Sales Q/Q	11.91%	Earnings	Apr 24 BMO	Avg Volume	974.73K	Price	17.00
SMA20	-5.17%	SMA50	-2.85%	SMA200	-15.87%	Trades		Volume	2,844,992	Change	3.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82

Show Previous Ratings

Today 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
07:00AM	Loading…
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	Loading…
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)
07:00AM	FDA Approves Novocures Innovative HFE Transducer Arrays for Use With Optune Gio for Glioblastoma (Business Wire)
Oct-31-24 07:30AM	NovoCures Strong Q3 and Leadership Changes in 2024 (TipRanks) -10.65%
03:04AM	NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com)
Oct-30-24 11:00PM	NovoCure (NVCR) Q3 2024 Earnings Call Transcript (Motley Fool)
08:15AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:02AM	Novocure Appoints Christoph Brackmann as Chief Financial Officer (Business Wire)
07:00AM	Novocure Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-17-24 10:52AM	Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment (GuruFocus.com) -5.43%
08:00AM	NovoCure scoops FDA approval on wearable for metastatic cancer treatment (Clinical Trials Arena)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
08:16AM	Novocure wins FDA approval for electric field device in lung cancer (BioPharma Dive)
07:28AM	FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients (Benzinga)
06:26AM	Novocure shares soar 33% as FDA approves lung cancer treatment (Investing.com)
03:45AM	NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily) +10.71%
04:43PM	FDA Approves Novocure's Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Oct-01-24 07:00AM	Novocure to Report Third Quarter 2024 Financial Results (Business Wire)
Sep-09-24 07:00AM	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Business Wire)
Sep-06-24 05:19PM	Why NovoCure Stock Dived by 13% This Week (Motley Fool) -6.48%
Sep-03-24 07:00AM	Novocure Announces Planned CEO Transition (Business Wire) -13.84%
Aug-28-24 07:00AM	Novocure to Participate in 2024 Wells Fargo Healthcare Conference (Business Wire) +9.61%
Aug-16-24 09:55AM	Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet (Zacks) -5.34%
Aug-14-24 07:00AM	Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer (Business Wire)
Aug-12-24 03:59PM	Biotech stocks: Which drugmakers are worth a buy? (Yahoo Finance Video)
Jul-30-24 09:55AM	Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade (Zacks) +12.24%
Jul-25-24 05:30PM	NovoCure (NVCR) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:11AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire) +7.17%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
Jul-01-24 07:00AM	Novocure to Report Second Quarter 2024 Financial Results (Business Wire)
Jun-14-24 10:44AM	Cramer's Lightning Round: Novocure, PayPal, AeroVironment (CNBC TV)
Jun-03-24 08:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival (Business Wire) +8.54%
May-23-24 05:05PM	TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany (Business Wire) -5.86%
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace) +13.01%
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.17%
May-03-24 12:08PM	NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:00AM	NovoCure (NVCR) Q1 2024 Earnings Call Transcript (Motley Fool)
May-02-24 01:19PM	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue (MT Newswires) +11.38%
11:56AM	NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:45AM	NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported (GuruFocus.com)
08:25AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:28AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon (Business Wire)
07:00AM	Novocure Reports First Quarter 2024 Financial Results (Business Wire)
Apr-25-24 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM
Paravasthu Mukund	Chief Operating Officer	Jan 11 '25	Sale	26.81	2,160	57,906	31,437	Jan 15 04:23 PM
MUKUND PARAVASTHU	Officer	Jan 13 '25	Proposed Sale	26.75	2,160	57,788		Jan 13 05:28 PM
WILHELMUS C. GROENHUYSEN	Officer	Jan 02 '25	Proposed Sale	29.80	266,085	7,929,333		Jan 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	Nov 02 '24	Sale	16.69	44	734	3,459	Nov 06 04:27 PM
Puri Michal Nath	Chief Human Resources Officer	Oct 31 '24	Sale	15.79	810	12,792	110,093	Nov 04 04:34 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Nov 01 '24	Sale	15.94	598	9,531	161,236	Nov 04 04:34 PM
Paravasthu Mukund	Chief Operating Officer	Nov 01 '24	Sale	15.88	160	2,540	3,503	Nov 04 04:32 PM
Cordova Ashley	Chief Financial Officer	Aug 02 '24	Sale	20.14	688	13,857	219,179	Aug 05 04:25 PM

Open in Screener

PODD

Insulet Corporation

Jun 06 • 04:00PM ET

311.77

Dollar change -5.39
Percentage change -1.70	%

Healthcare • Medical Devices • USA • NASD

PODD Insulet Corporation daily Stock Chart

Peers: DXCM JNJ ABT MDT EW SYK TNDM BSX BAX LIVN

| Held by: VTI VOO SPY IVV VB VO RSP XLV VUG IWP

Index	S&P 500	P/E	56.11	EPS (ttm)	5.56	Insider Own	0.51%	Shs Outstand	70.36M	Perf Week	-4.08%
Market Cap	21.94B	Forward P/E	57.39	EPS next Y	5.43	Insider Trans	-8.42%	Shs Float	70.02M	Perf Month	17.96%
Income	402.20M	PEG	2.03	EPS next Q	0.92	Inst Own	102.05%	Short Float	3.25%	Perf Quarter	23.81%
Sales	2.20B	P/S	9.98	EPS this Y	34.49%	Inst Trans	0.24%	Short Ratio	2.56	Perf Half Y	15.62%
Book/sh	18.91	P/B	16.49	EPS next Y	24.67%	ROA	13.10%	Short Interest	2.28M	Perf Year	71.48%
Cash/sh	18.23	P/C	17.10	EPS next 5Y	27.62%	ROE	37.92%	52W Range	173.00 - 329.33	Perf YTD	19.42%
Dividend Est.	-	P/FCF	75.29	EPS past 5Y	98.82%	ROI	13.67%	52W High	-5.33%	Beta	1.38
Dividend TTM	-	Quick Ratio	3.59	Sales past 5Y	22.92%	Gross Margin	71.14%	52W Low	80.21%	ATR (14)	8.24
Dividend Ex-Date	-	Current Ratio	4.43	EPS Y/Y TTM	71.25%	Oper. Margin	15.50%	RSI (14)	55.01	Volatility	0.55% 4.36%
Employees	3900	Debt/Eq	1.27	Sales Y/Y TTM	23.49%	Profit Margin	18.29%	Recom	1.52	Target Price	341.27
Option/Short	Yes / Yes	LT Debt/Eq	1.21	EPS Q/Q	-31.57%	Payout	0.00%	Rel Volume	0.76	Prev Close	317.16
Sales Surprise	4.73%	EPS Surprise	29.11%	Sales Q/Q	28.82%	Earnings	May 08 AMC	Avg Volume	890.55K	Price	311.77
SMA20	-2.96%	SMA50	10.69%	SMA200	19.99%	Trades		Volume	677,039	Change	-1.70%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-25	Initiated	Goldman	Buy	$380
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$350
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform	$340
Nov-06-24	Initiated	Bernstein	Outperform	$300
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight	$235 → $340
Oct-18-22	Initiated	Barclays	Equal Weight	$238
Oct-12-22	Initiated	Jefferies	Hold	$260
Jul-11-22	Downgrade	Citigroup	Buy → Neutral	$310 → $250
Mar-02-22	Resumed	BofA Securities	Buy	$300
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy	$320

Show Previous Ratings

Today 04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
Jun-05-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
12:01AM	3 Reasons Investors Love Insulet (PODD) (StockStory)
Jun-04-25 11:33PM	Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks (StockStory)
09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
11:30AM	Loading…
Jun-03-25 11:30AM	S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF (Zacks)
Jun-02-25 03:18PM	Solventum Stock Earns RS Rating Upgrade (Investor's Business Daily)
May-30-25 10:17AM	Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy (Investing.com)
May-26-25 08:30AM	Insulet Gains 78.5% in a Year: What's Driving the Stock? (Zacks)
May-23-25 06:01AM	Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire)
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks)
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
May-16-25 09:50AM	Here's Why Insulet (PODD) is a Strong Momentum Stock (Zacks)
05:51AM	Dexcom CEO says CGMs fit MAHA agenda very nicely; Tandem preps for new products (MedTech Dive)
May-15-25 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
12:45PM	Loading…
May-14-25 12:45PM	Insulet Corporation (PODD): Among the Stocks Analysts Are Upgrading Today (Insider Monkey)
08:45AM	Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer (MarketBeat)
07:20AM	Outlier Money Flows Lift Insulet (FX Empire)
May-13-25 06:00AM	Insulet Announces Publication of 2024 Sustainability Report (Business Wire)
May-12-25 09:10AM	Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised (Zacks)
May-10-25 11:47AM	S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points (Investor's Business Daily)
May-09-25 08:41PM	Analyst Report: Insulet Corporation (Morningstar Research) +20.88%
05:49PM	S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks (Investopedia)
05:49PM	S&P 500 Gains & Losses Today: Index Pulls Back Early Gains Amid Anticipation of Trade Talks (Investopedia)
04:02PM	Insulet Stock Soars To A High After Robust Earnings; This Customer Management Name Pops (Investor's Business Daily)
02:37PM	Insulet Stock Soars to Lead S&P 500 Gainers Friday (Investopedia)
02:16PM	Insulet Q1 beat, Sweetgreen sinks on outlook, Wolfspeed drops (Yahoo Finance Video)
11:57AM	Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More (Investopedia)
11:29AM	New Insulet CEO Ashley McEvoy sets priorities (MedTech Dive)
10:11AM	Insulet Stock Is the Top S&P 500 Performer Today. Heres Why. (Barrons.com)
08:21AM	Loading…
08:21AM	Q1 2025 Insulet Corp Earnings Call (Thomson Reuters StreetEvents)
03:39AM	Insulet Corp (PODD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion (GuruFocus.com)
May-08-25 07:01PM	Analyst Report: Insulet Corporation (Morningstar Research)
05:30PM	Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:11PM	Insulet Makes A Bullish Post-Earnings Move With A Beat-And-Raise (Investor's Business Daily)
04:11PM	Insulet Jumps After Beating Quarterly Forecasts, Raising 2025 Expectations (Investor's Business Daily)
04:10PM	Insulet: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1) (Business Wire)
May-07-25 05:20PM	Insulet Q1 2025 Earnings Preview (Seeking Alpha)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-05-25 09:15AM	Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
12:33AM	1 Growth Stock with Impressive Fundamentals and 2 to Think Twice About (StockStory)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
Apr-28-25 10:00AM	Insulet Names New CEO, Expects to Top Revenue Projections (Investopedia)
09:06AM	Ashley McEvoy named Insulet CEO (MedTech Dive)
09:04AM	1 Healthcare Stock Worth Your Attention and 2 to Turn Down (StockStory)
06:00AM	Insulet Appoints Ashley McEvoy President and CEO (Business Wire)
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks)
Apr-14-25 12:18PM	International Growth Drives GMED Stock Amid Fierce Competition (Zacks)
08:24AM	Bruker Stock May Benefit Following Its Investment in Ridom GmbH (Zacks)
Apr-13-25 08:38AM	Oakmark Bond Fund Q1 2025 Commentary (Seeking Alpha)
Apr-11-25 10:01AM	Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain? (Zacks)
Apr-10-25 05:17AM	Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? (Zacks) -5.01%
Apr-09-25 08:09AM	5 High-Flying Large-Cap Stocks to Buy Amid Tariff-Led Market Rout (Zacks) +7.16%
Apr-08-25 11:55AM	Oakmark Fixed Income Market Q1 2025 Commentary (Seeking Alpha)
10:02AM	PODD Stock Benefits From the Launch of Omnipod 5 in Canada (Zacks)
Apr-07-25 01:34PM	This Insulin Pump Maker Expands Into New Territory And Its Stock Shows Relative Strength (Investor's Business Daily)
07:07AM	Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above (PR Newswire)
Apr-03-25 02:25PM	Analyst Report: Insulet Corporation (Morningstar Research)
06:00AM	Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Mar-31-25 09:30AM	DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes (Zacks)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
01:38PM	Baird Q4 2024 Mid Cap Growth Strategy Commentary (Seeking Alpha)
Mar-27-25 10:50AM	Columbia Select Large Cap Growth Fund Q4 2024 Commentary (SeekingAlpha)
05:14AM	3 Reasons Investors Love Insulet (PODD) (StockStory)
Mar-24-25 08:09AM	Insulet Gains 62.9% in a Year: What's Driving the Stock? (Zacks)
Mar-21-25 12:36PM	PODD Stock Gains Following the Launch of Omnipod 5 in Australia (Zacks)
08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
08:19AM	DGX Stock Set to Benefit From New Google Cloud Partnership (Zacks)
05:06AM	Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers (StockStory)
Mar-20-25 12:41PM	PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5 (Zacks)
08:23AM	LendingTree and AMC Networks have been highlighted as Zacks Bull and Bear of the Day (Zacks)
05:54AM	Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data (MedTech Dive)
Mar-19-25 04:01PM	Insulets RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections (Business Wire)
11:03AM	3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan (Zacks)
Mar-18-25 04:32PM	Insulet Announces Pricing of Senior Notes Due 2033 (Business Wire)
01:51PM	Insulet Corporation (PODD): Among the Best Diabetes Stocks to Buy According to Billionaires (Insider Monkey)
10:35AM	Insulet Chief Technology Officer Mark Field leaves (MedTech Dive)
07:35AM	Insulet Announces Proposed Financing Transactions (Business Wire)
06:05AM	Insulet Expands Omnipod 5 to Four More International Markets (Business Wire)
06:00AM	From Injections to Innovation Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod 5 in Adults and Children with Type 1 Diabetes (Business Wire)
Mar-11-25 06:00AM	Insulet to Host Investor Day on June 5, 2025 (Business Wire)
Mar-07-25 09:41AM	Robinhood initiated, MongoDB downgraded: Wall Streets top analyst calls (TipRanks)
Feb-27-25 09:23PM	Analyst Report: Insulet Corporation (Morningstar Research)
06:49AM	Tandems insulin pump tech wins FDA nod for Type 2 diabetes (MedTech Dive)
04:05AM	Reflecting On Patient Monitoring Stocks Q4 Earnings: DexCom (NASDAQ:DXCM) (StockStory)
Feb-26-25 08:04AM	Insulet Sales Keep Rising (FX Empire)
Feb-25-25 02:52PM	Medtronic Stock Gets IBD Rating Lift (Investor's Business Daily) -5.93%
Feb-21-25 01:28PM	Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst (Benzinga)
10:45AM	Analyst Report: Insulet Corporation (Morningstar Research)
02:15AM	Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com)
Feb-20-25 05:30PM	Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Insulet (PODD) Q4 Earnings and Revenues Top Estimates (Zacks)
04:35PM	Insulets (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations (StockStory)
04:33PM	Insulet: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year (Business Wire)
Feb-19-25 08:11AM	Insulet Earnings: What To Look For From PODD (StockStory)
Feb-14-25 09:15AM	Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Jan-13-25 04:01PM	Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe (Business Wire)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hollingshead James	Former Officer	May 16 '25	Proposed Sale	323.10	15,605	5,041,964		May 16 04:40 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Option Exercise	95.43	5,278	503,680	28,458	May 15 04:25 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Sale	318.47	5,278	1,680,885	23,180	May 15 04:25 PM
Hopfield Jessica	Director	May 13 '25	Option Exercise	28.87	5,235	151,134	32,152	May 14 04:15 PM
Hopfield Jessica	Director	May 13 '25	Sale	317.54	5,235	1,662,322	26,917	May 14 04:15 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Option Exercise	92.11	3,001	276,422	23,907	May 14 04:08 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Sale	320.00	3,001	960,320	20,906	May 14 04:08 PM
Kapples John W.	Officer	May 14 '25	Proposed Sale	318.47	5,278	1,680,901		May 14 12:32 PM
Field Mark N	Former Officer	May 13 '25	Proposed Sale	321.31	2,457	789,459		May 13 01:44 PM
Benjamin Eric	Officer	May 13 '25	Proposed Sale	320.00	3,001	960,320		May 13 12:51 PM
Hopfield Jessica	Director	May 13 '25	Proposed Sale	317.54	5,235	1,662,322		May 13 10:19 AM
Frederick Wayne A.I.	Director	Mar 25 '25	Sale	275.00	1,825	501,875	3,231	Mar 26 04:22 PM
Frederick Wayne A.I.	Director	Mar 25 '25	Proposed Sale	275.00	1,825	501,875		Mar 25 10:30 AM
Benjamin Eric	EVP, CPXO	Mar 03 '25	Option Exercise	56.52	5,146	290,873	20,906	Mar 04 04:09 PM
Benjamin Eric	EVP, CPXPO	Jan 21 '25	Option Exercise	65.00	5,075	329,898	23,777	Jan 22 04:10 PM
Benjamin Eric	EVP, CPXPO	Jan 21 '25	Sale	280.00	12,394	3,470,320	11,383	Jan 22 04:10 PM
Benjamin Eric	Officer	Jan 21 '25	Proposed Sale	280.00	12,394	3,470,320		Jan 21 10:56 AM
Benjamin Eric	EVP, CPXPO	Dec 16 '24	Sale	267.60	4,362	1,167,271	18,702	Dec 17 04:14 PM
Benjamin Eric	Officer	Dec 16 '24	Proposed Sale	267.60	4,362	1,167,271		Dec 16 10:38 AM
Budden Lauren	Group VP, CAO and Controller	Dec 10 '24	Sale	275.62	915	252,192	5,733	Dec 11 04:00 PM
Budden Lauren	Officer	Dec 10 '24	Proposed Sale	275.62	915	252,194		Dec 10 05:18 PM
BORIO LUCIANA	Director	Nov 12 '24	Sale	274.80	508	139,598	2,790	Nov 13 04:01 PM
BORIO LUCIANA	Director	Nov 12 '24	Proposed Sale	274.81	508	139,602		Nov 12 04:01 PM
Hopfield Jessica	Director	Sep 11 '24	Option Exercise	29.87	7,628	227,848	34,545	Sep 12 04:07 PM
Hopfield Jessica	Director	Sep 11 '24	Sale	225.26	7,628	1,718,283	26,917	Sep 12 04:07 PM
Scannell Timothy J	Director	Sep 10 '24	Sale	225.84	5,000	1,129,200	30,586	Sep 11 04:13 PM
Hopfield Jessica	Director	Sep 11 '24	Proposed Sale	225.26	7,628	1,718,283		Sep 11 03:40 PM
Field Mark N	SVP & Chief Technology Officer	Sep 09 '24	Sale	220.87	1,383	305,463	9,761	Sep 10 04:16 PM
Budden Lauren	Group VP, CAO and Controller	Sep 09 '24	Sale	221.41	1,506	333,443	6,609	Sep 10 04:15 PM
Scannell Timothy J	Director	Sep 10 '24	Proposed Sale	225.84	5,000	1,129,210		Sep 10 02:27 PM
Field Mark N	Officer	Sep 09 '24	Proposed Sale	220.87	1,383	305,465		Sep 09 04:50 PM
Budden Lauren	Officer	Sep 09 '24	Proposed Sale	221.41	1,506	333,436		Sep 09 01:20 PM
Singh Prem	SVP, Global Operations	Aug 30 '24	Sale	202.27	1,824	368,940	3,656	Sep 03 04:30 PM
Singh Prem	Officer	Aug 30 '24	Proposed Sale	202.27	1,824	368,938		Aug 30 03:22 PM
Chadwick Ana Maria	EVP, CFO & Treasurer	Aug 29 '24	Buy	206.00	100	20,600	13,314	Aug 29 04:17 PM
Field Mark N	SVP & Chief Technology Officer	Aug 28 '24	Sale	203.00	1,387	281,561	11,347	Aug 29 04:14 PM
Field Mark N	Officer	Aug 28 '24	Proposed Sale	203.00	1,387	281,561		Aug 28 04:02 PM
Field Mark N	SVP & Chief Technology Officer	Jun 14 '24	Sale	199.96	1,500	299,940	12,875	Jun 17 04:11 PM
Scannell Timothy J	Director	Jun 10 '24	Sale	190.51	7,000	1,333,570	35,586	Jun 11 04:12 PM
Field Mark N	SVP & Chief Technology Officer	Jun 10 '24	Sale	190.43	2,131	405,806	14,375	Jun 11 04:11 PM

NVCR

NovoCure Ltd

PODD

Insulet Corporation

Upgrade your FINVIZ experience